"Cut-to-the-Chase Members”
Make Potential Profit Of 80.5%And More Is Likely!

As Well, Another
Options Trade Included!

Immunomedics
stock pricefell as low as $16.80 yesterday and closed the day down 2.46%.
This was great for “Cut-to-the-Chase
Members”, sitting on a put option, realizing a potential profit of 80.5% at
this stage! The original recommendation was based on an operating loss increase
as well as negative earnings report.

Immunomedics stock has risen over 100% in the last
year on the heels of promising data from clinical trials investigating
sacituzumab govitecan as a potential treatment for various solid tumors. The
company filed a biologics license application (BLA) with the U.S. Food and Drug
Administration (FDA) seeking regulatory approval for the drug as a treatment in
metastatic triple-negative breast cancer (mTNBC). The application was accepted
months ago, and now investors are simply waiting for a regulatory decision on
Jan. 18, 2019 -- hoping for approval.

However, the business racked up an operating loss
of $57.1 million in the most recent quarter. That compares to an operating loss
of $21.6 million in the year-ago period, although nearly all of the difference
can be explained by an increase in research and development (R&D) spending
for the company's maturing pipeline and preparation for the potential approval
and market launch of its first product.

As well, Immunomedics came out with a quarterly
loss of $0.35 per share versus the Consensus Estimate of a loss of $0.28. This compares
to loss of $0.16 per share a year ago. These figures are adjusted for
non-recurring items.

This quarterly report represents an earnings
surprise of -25%. A quarter ago, it was expected that this biopharmaceutical
company would post a loss of $0.20 per share when it actually produced a loss
of $0.34, delivering a surprise of -70%.

Over the last four quarters, the company has not
been able to surpass consensus EPS estimates.....

Shares of Immunomedics fell nearly 11%
today after the company reported fiscal first-quarter 2019 operating results.
Immunomedics is a pre-commercial business, so there's not much for investors to
peer into except, perhaps, the magnitude of operating losses accrued as the
company attempts to transition to a commercial-stage entity.

On that note, the business racked up an
operating loss of $57.1 million in the most recent quarter. That compares to an
operating loss of $21.6 million in the year-ago period, although nearly all of
the difference can be explained by an increase in research and development
(R&D) spending for the company's maturing pipeline and preparation for the
potential approval and market launch of its first product.

And since then has moved with the overall
market movement, up and down, but now experiencing more down then up.

The Profits.....

So, for
“Cut-to-the-Chase” members, who managed to execute this trade
recommended by Stock Options Made Easy; potential profits of 80.5% were available
yesterday.

Entering
the option trade at a cost of $1.75 or less; and the price of the option reached
$3.16 yesterday; a profit of 80.5% was made in a couple of weeks. Therefore, one
options contract would provide a profit of $141.00.

A NICE START TO THE WEEK!

Moving
Forward…..

Immunomedics stock has risen over 100% in the last year on the heels of
promising data from clinical trials investigating sacituzumab govitecan as a
potential treatment for various solid tumors. The company filed a biologics
license application (BLA) with the U.S. Food and Drug Administration (FDA)
seeking regulatory approval for the drug as a treatment in metastatic triple-negative
breast cancer (mTNBC). The application was accepted months ago, and now
investors are simply waiting for a regulatory decision on Jan. 18, 2019 – and hoping
for approval.

Therefore, swelling operating expenses are not surprising by any means
given the circumstances.

Additionally, Immunomedics announced that it had expanded its current
collaboration with AstraZeneca to include metastatic non-small cell lung
cancer indications.

Immunomedics remains on track for receiving a regulatory decision for
its first product in early January 2019, has continued to investigate the
drug's use in additional clinical trials, and even signed a long-term
manufacturing contract with Samsung Biologics in September that will see the
company pay out $82 million in the next three years for key components of the
final drug product.

With the market volatility continuing to cause the stock price to
falter, as well as the increased nervousness of investors waiting for
sacituzumab govitecan to be approved in January; it is likely that the stock
will continue downwards for the short-term before reversing direction.

Also worth considering is that seven analysts have rated the stock with
a buy rating and one has given a strong buy rating to the company; and that
Immunomedics currently has an average rating of Buy and a consensus price
target of $38.43.

This is where the following suggested options trade comes into play with
the expectation that the approval for the drug will be successful!

As you
would have by now realized, some of our trades are based on earnings
predictions. This is not to say all trades recommended to members follow this
pattern, and it is obvious that it did originally apply in this case; and
during earnings season this strategy of predicting earnings has been very
profitable.

Sometimes it is our approach to predict
whether a company will beat or miss estimates, whether the stock will
appreciate or depreciate as a result and what strategies investors and traders
can use – such as found with the “Earnings Predictions Program”. This type of
prediction is based on thorough investigation and fundamentally based research,
and the results have been very exceptional.

It is also worth
considering, when options trading earnings reports – “Do we exit on
already existing profits or leave the companies to report their earnings and
hope for bigger profit?”.....READ MORE.....